MedTrace Logo

Frailty Phenotype Assessments to Optimize Treatment Strategies for Older Patients With Hematologic Malignancies

NCT03680677 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2025-07-31

No results posted yet for this study

Summary

The purpose of this research study is to determine if frailty assessments can be used to predict how well patients aged 60 years and older will do after chemotherapy, CAR T-cell therapy, or allogeneic stem cell transplant.

Conditions

  • Leukemia, Acute
  • MDS

Interventions

PROCEDURE

Bone Marrow or Peripheral Blood Graft (BMT)

Patient receives bone marrow or peripheral blood graft (BMT) on or off protocol.

OTHER

Cancer-directed Therapy or Best Supportive Care

Cancer-directed therapy with intensive regimens ("7+3," Vyxeos, clofarabine, or similar), clinical trial, hypomethylating agent (azacitidine or decitabine), hypomethylating agent combinations (i.e. with venetoclax, sorafenib, enasidenib, ivosidenib, midostaurin, gilteritinib, or other targeted agent), targeted agents alone (i.e. enasidenib, ivosidenib, gilteritinib, midostaurin, etc.), or supportive care.

DIAGNOSTIC_TEST

Frailty Assessment

Frailty is the vulnerability of older adults to adverse health outcomes in response to illness and iatrogenic stressors.

Sponsors & Collaborators

  • Abramson Cancer Center at Penn Medicine

    lead OTHER

Principal Investigators

  • Shannon McCurdy, MD · Abramson Cancer Center

Eligibility

Min Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-09-21
Primary Completion
2026-06-22
Completion
2026-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03680677 on ClinicalTrials.gov